Published in J Clin Oncol on September 10, 2008
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol (2009) 2.73
Small cell lung cancer. J Natl Compr Canc Netw (2013) 2.04
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer (2011) 1.16
Treatment options for small cell lung cancer - do we have more choice? Br J Cancer (2010) 1.07
Progress in small-cell lung cancer: the lowest common denominator. J Clin Oncol (2008) 0.95
Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer. J Clin Oncol (2009) 0.90
The EphB4 receptor tyrosine kinase promotes lung cancer growth: a potential novel therapeutic target. PLoS One (2013) 0.90
Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. J Thorac Oncol (2013) 0.87
The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. Onco Targets Ther (2015) 0.82
Combined MET inhibition and topoisomerase I inhibition block cell growth of small cell lung cancer. Mol Cancer Ther (2013) 0.81
Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer. Onco Targets Ther (2015) 0.80
Paclitaxel-etoposide-carboplatin/cisplatin versus etoposide-carboplatin/cisplatin as first-line treatment for combined small-cell lung cancer: a retrospective analysis of 62 cases. Cancer Biol Med (2015) 0.77
The impact of individual quality of life assessment on psychosocial attention in patients with chest malignancies: a randomized study. Support Care Cancer (2012) 0.77
Efficacy and safety of angiogenesis inhibitors in small-cell lung cancer. Oncotarget (2016) 0.76
Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer. BMC Cancer (2016) 0.75
Should irinotecan or etoposide be used in combination with carboplatin for small cell lung cancer? Nat Clin Pract Oncol (2009) 0.75
Small-cell lung cancer with recurrent syncope as the initial symptom: A case report and literature review. Mol Clin Oncol (2016) 0.75
Chemotherapy: Irinotecan or etoposide as front-line therapy for SCLC? Nat Rev Clin Oncol (2009) 0.75
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses. Thorac Cancer (2017) 0.75
Irinotecan and Carboplatin (IC) Regimen for Small-Cell Lung Cancer and Non-Small-Cell Lung Cancer. Hosp Pharm (2014) 0.75
Systemic Chemotherapy for Progression of Brain Metastases in Extensive-Stage Small Cell Lung Cancer. Case Rep Oncol Med (2015) 0.75
The Humanistic Burden of Small Cell Lung Cancer (SCLC): A Systematic Review of Health-Related Quality of Life (HRQoL) Literature. Front Pharmacol (2017) 0.75
Meta-analysis of the role of bevacizumab in extensive stage small cell lung cancer. Oncol Lett (2017) 0.75
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol (2009) 3.66
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol (2002) 2.65
Long-term results of the international adjuvant lung cancer trial evaluating adjuvant Cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol (2009) 2.50
Lung cancer survival and stage at diagnosis in Australia, Canada, Denmark, Norway, Sweden and the UK: a population-based study, 2004-2007. Thorax (2013) 2.19
Radiological and clinical outcomes of using Chartis™ to plan endobronchial valve treatment. Eur Respir J (2012) 2.07
Prevalence of olfactory dysfunction: the skövde population-based study. Laryngoscope (2004) 2.06
Phase III study by the Norwegian lung cancer study group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.93
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial. J Clin Oncol (2004) 1.85
WNT7a induces E-cadherin in lung cancer cells. Proc Natl Acad Sci U S A (2003) 1.78
Is there a prognostic role of K-ras point mutations in the serum of patients with advanced non-small cell lung cancer? Lung Cancer (2005) 1.57
The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer (2003) 1.47
Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma. Cancer Res (2002) 1.22
Stereotactic body radiotherapy for medically inoperable patients with stage I non-small cell lung cancer - a first report of toxicity related to COPD/CVD in a non-randomized prospective phase II study. Radiother Oncol (2008) 1.20
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial. Clin Cancer Res (2011) 1.18
Influence of comorbidity on survival, toxicity and health-related quality of life in patients with advanced non-small-cell lung cancer receiving platinum-doublet chemotherapy. Eur J Cancer (2010) 1.13
Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy. J Thorac Oncol (2009) 1.13
The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer. J Pain Symptom Manage (2007) 1.10
Study of anxiety disorder and depression in long-term survivors of testicular cancer. J Clin Oncol (2005) 1.06
Long-term follow-up of cancer patients receiving radiotherapy for bone metastases: results from a randomised multicentre trial. Radiother Oncol (2009) 1.00
Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Eur J Cancer (2011) 0.97
Is the sexual function compromised in long-term testicular cancer survivors? Eur Urol (2007) 0.97
Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. Cochrane Database Syst Rev (2015) 0.96
Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol (2012) 0.96
Fear of recurrence in long-term testicular cancer survivors. Psychooncology (2009) 0.96
A systematic overview of radiation therapy effects in non-small cell lung cancer. Acta Oncol (2003) 0.95
Side effects and cancer-related stress determine quality of life in long-term survivors of testicular cancer. J Clin Oncol (2005) 0.95
Pulmonary function in long-term survivors of testicular cancer. J Clin Oncol (2009) 0.93
NTCP modelling of lung toxicity after SBRT comparing the universal survival curve and the linear quadratic model for fractionation correction. Acta Oncol (2011) 0.90
Reduced pulmonary function is associated with lower levels of endogenous total and free testosterone. The Tromsø study. Eur J Epidemiol (2007) 0.89
Chemotherapy and quality of life in NSCLC PS 2 patients. Acta Oncol (2009) 0.89
Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol (2012) 0.88
In the shadow of bad news - views of patients with acute leukaemia, myeloma or lung cancer about information, from diagnosis to cure or death. BMC Palliat Care (2007) 0.88
Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res (2008) 0.88
Health related quality of life in locally advanced NSCLC treated with high dose radiotherapy and concurrent chemotherapy or cetuximab--pooled results from two prospective clinical trials. Radiother Oncol (2012) 0.88
Expression and clinical significance of the proliferation marker minichromosome maintenance protein 2 (Mcm2) in diffuse astrocytomas WHO grade II. Diagn Pathol (2013) 0.87
A prospective phase II study: high-dose pemetrexed as second-line chemotherapy in small-cell lung cancer. Lung Cancer (2008) 0.86
Changes in the Secretory Profile of NSCLC-Associated Fibroblasts after Ablative Radiotherapy: Potential Impact on Angiogenesis and Tumor Growth. Transl Oncol (2013) 0.85
Assessing quality of life in a randomized clinical trial: correcting for missing data. BMC Med Res Methodol (2009) 0.85
Treatment outcome in performance status 2 advanced NSCLC patients administered platinum-based combination chemotherapy. Lung Cancer (2008) 0.85
Dyspnea experience in patients with lung cancer in palliative care. Eur J Oncol Nurs (2007) 0.84
Predictors of oxygen saturation ≤95% in a cross-sectional population based survey. Respir Med (2012) 0.84
One-way endobronchial valve for bronchopleural fistula after necrotizing pneumonia. Asian Cardiovasc Thorac Ann (2013) 0.83
Cyclooxygenase-2 expression in lung cancer cells evaluated by immunocytochemistry. Diagn Cytopathol (2011) 0.83
Qualify of life and palliation predict survival in patients with chronic alveolar hypoventilation and nocturnal ventilatory support. Qual Life Res (2009) 0.82
Heterogeneity in gamma-glutamyltransferase mRNA expression and glycan structures. Search for tumor-specific variants in human liver metastases and colon carcinoma cells. Biochim Biophys Acta (2003) 0.82
Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy. Eur J Cancer (2012) 0.81
Poor prognosis patients with inoperable locally advanced NSCLC and large tumors benefit from palliative chemoradiotherapy: a subset analysis from a randomized clinical phase III trial. J Thorac Oncol (2014) 0.81
Diagnostic yield and efficacy of endobronchial ultrasound-guided transbronchial needle aspiration in mediastinal lymphadenopathy. Clin Respir J (2011) 0.81
Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? J Thorac Oncol (2006) 0.80
A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer (2012) 0.80
A study of coping in long-term testicular cancer survivors. Psychol Health Med (2010) 0.80
Impact of home mechanical ventilation on health-related quality of life in patients with chronic alveolar hypoventilation: a prospective study. Clin Respir J (2008) 0.80
[Recurrence and survival after surgical treatment of lung cancer]. Tidsskr Nor Laegeforen (2010) 0.79
Potentially curative radiotherapy for non-small-cell lung cancer in Norway: a population-based study of survival. Int J Radiat Oncol Biol Phys (2010) 0.79
Validity, reliability and clinical relevance of EORTC QLQ-C30 and LC13 in patients with chest malignancies in a palliative setting. Qual Life Res (2007) 0.79
Randomized phase II study of gemcitabine and carboplatin +/- sequential docetaxel in non-small cell lung cancer. Lung Cancer (2010) 0.79
Primary human glioblastomas - prognostic value of clinical and histopathological parameters. Clin Neuropathol (2012) 0.78
Dyspnea experience and management strategies in patients with lung cancer. Psychooncology (2008) 0.78
Validation of a Swedish version of the Cancer Dyspnea Scale. J Pain Symptom Manage (2006) 0.77
A longitudinal study of the Swedish Self-Evaluation of Communication Experiences after Laryngeal Cancer questionnaire in patients treated for laryngeal cancer. Acta Oncol (2002) 0.77
Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)? Data from a prospective randomised study. Radiother Oncol (2005) 0.77
The impact of individual quality of life assessment on psychosocial attention in patients with chest malignancies: a randomized study. Support Care Cancer (2012) 0.77
The Assessment of Quality of life at the End of Life (AQEL) questionnaire: a brief but comprehensive instrument for use in patients with cancer in palliative care. Qual Life Res (2010) 0.76
[Mutation testing for non-small-cell lung cancer]. Tidsskr Nor Laegeforen (2012) 0.76
Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol (2007) 0.76
[Surgical treatment of lung cancer]. Tidsskr Nor Laegeforen (2004) 0.75
[Lung cancer--a low status disease?]. Tidsskr Nor Laegeforen (2002) 0.75
A controlled study of risk factors for disease and current problems in long-term testicular cancer survivors. J Cancer Surviv (2010) 0.75
[Bronchopleural fistula treated with endobronchial vent placement. Successful treatment of feared lung complication]. Lakartidningen (2013) 0.75
Management satisfaction in survivors of testicular cancer. Anticancer Res (2006) 0.75
Pancreatic polypeptide is increased in patients with advanced malignant disease. Anticancer Res (2004) 0.75
Prognostic factors for the survival of surgically treated patients for non-small cell lung cancer. Acta Oncol (2003) 0.75
Multicentre phase II trial of paclitaxel and carboplatin with concurrent radiotherapy in locally advanced non-small cell lung cancer. Anticancer Res (2008) 0.75
Can dogs smell lung cancer? First study using exhaled breath and urine screening in unselected patients with suspected lung cancer. Acta Oncol (2013) 0.75
Current Practice of Airway Stenting in the Adult Population in Europe: A Survey of the European Association of Bronchology and Interventional Pulmonology (EABIP). Respiration (2017) 0.75
Prophylactic treatment of local reactions to i.v. vinorelbine: a randomized study. Support Care Cancer (2011) 0.75
[Lung cancer--of more current interest than before]. Tidsskr Nor Laegeforen (2006) 0.75